Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating Sleep Apnea Risk in Survivors of Intracerebral Hemorrhage in the REDUCE Cohort
Sleep
P9 - Poster Session 9 (8:00 AM-9:00 AM)
9-002

There are well-described racial and ethnic disparities in ICH. OSA is a recently identified risk factor for ICH. We analyzed data from ICH survivors in the ongoing REDUCE trial to determine whether race/ethnicity was associated with higher versus lower risk of OSA.

Exploratory analysis of obstructive sleep apnea (OSA) risk in survivors of intracerebral hemorrhage (ICH) enrolled in the REDUCE trial.

 

The Berlin questionnaire (BQ), a 10-item questionnaire to assess OSA risk, is validated in stroke survivors. Our analysis was conducted on data from 59 subjects enrolled across all five sites of the REDUCE trial, a pragmatic, randomized, open-label trial comparing the effect of a spironolactone-containing antihypertensive regimen versus a standard regimen in survivors of ICH. Subjects completed the BQ at the time of enrollment and were stratified as high versus low risk for OSA using standard definitions. Independent samples t-tests, two-sample z-tests for proportions, and chi-squared analyses were used to assess differences between high and low risk groups. 

 

Of the 59 subjects, 40.7% were female, 35.6% were Black, 11.9% identified as Hispanic, the average age was 62.5 ± 12.1, and the median number of days post-ICH was 116. High risk scores were assigned to 28 (47.5%) subjects; 31 (52.5%) were low risk. The two groups were balanced for sex and BMI. The average age of the low-risk group was higher (66.4 vs. 58.2 in high risk, p = 0.008). There was no association between race and OSA risk (p = 0.313). Subjects identifying as Hispanic were significantly more likely to be at high risk for OSA than subjects identifying as non-Hispanic (85.7% versus 42.3%, p = 0.031).

Hispanic ICH survivors were more likely to be at high risk for OSA than non-Hispanic ICH survivors. This preliminary finding should be confirmed in a larger cohort.

Authors/Disclosures
Emma S. Peasley (Yale School of Medicine)
PRESENTER
Miss Peasley has nothing to disclose.
No disclosure on file
Julia Zabinska Ms. Zabinska has nothing to disclose.
Rachel Forman, MD (Yale Neurology) Dr. Forman has nothing to disclose.
Dheeraj D. Lalwani (Yale University School of Medicine, Department of Neurology) Mr. Lalwani has nothing to disclose.
No disclosure on file
Guido J. Falcone, MD (Yale School of Medicine) The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.
Rohan Arora, MD The institution of Dr. Arora has received research support from Bayer.
No disclosure on file
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Munachi N. Okpala, NP (McGovern Medical School-Division of Adult Neurology, Stroke Team) Ms. Okpala has nothing to disclose.
Cheryl Bushnell, MD, MHS (Wake Forest School of Medicine) Dr. Bushnell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZZ Biotech. The institution of Dr. Bushnell has received research support from PCORI. The institution of Dr. Bushnell has received research support from AHRQ. The institution of Dr. Bushnell has received research support from NIH/NINDS. Dr. Bushnell has received intellectual property interests from a discovery or technology relating to health care. Dr. Bushnell has received publishing royalties from a publication relating to health care.
Michael T. Mullen, MD (Temple University) Dr. Mullen has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Steven R. Messe, MD, FAHA, FAAN (Hospital of the University of Pennsylvania) Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.